EEG Biosensors segmentation by application delineates four primary demand drivers. Clinical monitoring encompasses hospital‑based neurodiagnostic procedures, intensive‑care seizure surveillance, and intra‑operative brain mapping, representing the largest share due to high‑volume device procurement and reimbursement frameworks. Research & development covers academic and pharmaceutical laboratories that require high‑resolution, multi‑channel platforms for neuroscience studies and drug‑target validation; its growth is propelled by expanding funding for brain‑computer interface projects. Neurofeedback and rehabilitation includes therapeutic programs for stroke, ADHD, and anxiety that employ real‑time EEG feedback, contributing a moderate portion of revenue as insurers gradually endorse such interventions. Consumer wellness pertains to portable headsets for sleep tracking, meditation, and fitness, a niche yet fast‑growing segment driven by lifestyle adoption. Collectively, these application categories shape the overall EEG Biosensors market size, with clinical monitoring alone accounting for roughly 45 % of total sales, followed by research (30 %), neurofeedback (15 %), and consumer wellness (10 %). Regulatory approvals and reimbursement policies further amplify clinical adoption, while advances in signal‑processing algorithms expand research and consumer use cases.